Moran Wealth Management LLC Makes New Investment in ADMA Biologics Inc (NASDAQ:ADMA)

Moran Wealth Management LLC bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 40,056 shares of the biotechnology company's stock, valued at approximately $795,000.

A number of other institutional investors have also made changes to their positions in the stock. Mark Sheptoff Financial Planning LLC acquired a new position in shares of ADMA Biologics in the 4th quarter worth approximately $35,000. Vision Financial Markets LLC purchased a new stake in ADMA Biologics in the fourth quarter valued at approximately $51,000. Farther Finance Advisors LLC lifted its stake in ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 2,505 shares in the last quarter. AlphaQuest LLC acquired a new position in ADMA Biologics during the fourth quarter worth $84,000. Finally, GF Fund Management CO. LTD. purchased a new position in shares of ADMA Biologics during the fourth quarter worth $85,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Up 0.3%

ADMA Biologics stock traded up $0.05 during trading on Monday, reaching $18.21. The stock had a trading volume of 4,647,159 shares, compared to its average volume of 3,702,803. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. ADMA Biologics Inc has a 52-week low of $10.21 and a 52-week high of $25.67. The stock has a market cap of $4.35 billion, a PE ratio of 21.42 and a beta of 0.47. The business has a 50 day moving average price of $20.54 and a 200 day moving average price of $18.74.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The firm had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. ADMA Biologics's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.08 earnings per share. On average, analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial lifted their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. The trade was a 69.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the transaction, the director owned 478,194 shares in the company, valued at $10,190,314.14. The trade was a 2.05% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 464,621 shares of company stock valued at $9,644,269. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.